MÉRIEUX-EQUITY
AcuSurgical, a Montpellier-based company focused on robotic microsurgery, today announces a €5.75 million Series A financing round led by Mérieux Equity Partners (via OMX Europe Venture Fund) and Supernova Invest (via Supernova 2 Fund), with Sofimac Innovation (via Pertinence Invest 2 Fund) and IRDI Capital Investissement (via Irdinov 2 and Inn’Vest PME Occitanie Est Funds) participating in the round.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210217005035/en/
Using advanced robotics, AcuSurgical is making ocular microsurgery safer and more accessible by dramatically improving the precision of surgical interventions. A proof of concept of the platform has already been completed with a first prototype validated in a preclinical setting.
The company will use the proceeds of the Series A financing to conduct clinical trials and reach regulatory approval with vitreo-retinal surgery as the first indication, paving the way for future applications that are not within the reach of surgeons today.
Retinal surgeries represent an annual global market of 1.6 million procedures, currently performed by a limited number of specialized surgeons. AcuSurgical’s robotic platform aims to increase the precision of current procedures, filtering tremor and augmenting visualization with the aid of a telemanipulated robot, while the surgeon remains in complete control.
Founded by Christoph Spuhler, serving as Chief Executive Officer, AcuSurgical has already attracted an experienced and highly skilled multidisciplinary team of executives, alongside the scientific co-founders, Prof. Yassine Haddab and Prof. Philippe Poignet, robotics experts at the joint research Unit LIRMM (Laboratory of Computer Science, Robotics and Microelectronics in Montpellier) and Prof. Philippe Gain and Prof. Gilles Thuret, retinal surgeons at the Saint-Etienne University Hospital.
“Our ambition is to enable new treatments for retinal disease that will open new perspectives for the numerous patients who are impacted by these debilitating retinal conditions. We are proud of the vote of confidence by this strong syndicate of investors. This financing will allow us to grow the team and reach key milestones towards certification and commercialisation of a truly innovative surgical solution”, s ays Christoph Spuhler, CEO and co-founder of AcuSurgical.
“We are delighted to partner with such an experienced team and look forward to supporting AcuSurgical in bringing to market a novel solution that will improve ocular surgeries and open new procedures in ophthalmology” , says Valérie Calenda, Managing Partner at Mérieux Equity Partners.
”The robotics platform developed by AcuSurgical aims to help retinal surgeons perform complex procedures more safely and reproducibly. We are very pleased to support this new venture and excellent team” says Celia Hart, General Partner at Supernova Invest.
About AcuSurgical - www.acusurgical.com
Founded in 2020, AcuSurgical is a surgical robotics company based in Montpellier (France). AcuSurgical's mission is to enable top-class treatment to the 300+ million patients suffering from retinal disease worldwide, a debilitating condition including age-related macular degeneration (AMD), diabetic retinopathy and macular holes. Worldwide, currently 1.6 million retinal surgeries are performed each year, with a yearly growth rate of 7%. This currently represents only a small percentage of actual cases, with the majority of patients, especially in emerging economies, getting inadequate treatment or often no treatment at all. The cutting-edge robotics platform from AcuSurgical aims to change this, bringing a new surgical paradigm to vitreo-retinal surgery based on precision robotics.
About Mérieux Equity Partners - www.merieux-partners.com
Mérieux Equity Partners (“MxEP”) is an investment company dedicated to capital investment in health and nutrition and registered with the Autorité des Marchés Financiers (AMF). MxEP actively supports entrepreneurs and companies with differentiated products and services, giving them privileged access to its sector expertise and international network. MxEP currently manages around €670 million of assets and launched their latest venture capital fund in 2020, OMX Venture Fund, to finance high potential companies in the life science space, in Europe and North America.
About Supernova Invest - www.supernovainvest.com
Supernova Invest is a cutting-edge venture capital firm with a leading position in the French deeptech investment market. It manages and advises five capital funds for a total of €260 million AUM. Supernova Invest specializes in breakthrough technologies, developing start-ups in Industry, Health, Energy & Environment and Digital Technology sectors. Supernova Invest has a strong partnership with both the CEA (the French Alternative Energies and Atomic Energy Commission) and Amundi (the European leader in asset management).
The FPCI Supernova 2 is an early-stage investment fund managed by Supernova Invest. Its main investors are the Crédit Agricole, the Fond National d’Amorçage managed by Bpi France, the CEA, Michelin, BioMérieux, Vinci, EDF, CGG, UDIMEC as well as entrepreneurs and family offices.
About Sofimac Innovation - www.sofimacinnovation.com
Sofimac Innovation is an independent management company certified by the financial markets regulator (AMF) and dedicated to technological and innovative investment. Based in Paris, Lyon, Rennes and Marseille, Sofimac Innovation supports innovative start-up in their growth projects with a wide range of investment vehicles. Working in a wide variety of technological sectors, particularly in Health and Digital sectors, Sofimac Innovation is currently managing 9 Funds comprising around 90 active companies.
Pertinence Invest 2 is an investment Fund managed by Sofimac Innovation, raised in partnership with prestigious Universities and Schools and renowned industrial corporates. Pertinence Invest 2 is investing in breakthrough technologies in the Engineering Sciences and Health & Nutrition sectors.
About IRDI Capital Investissement - www.irdi.fr
Based in Toulouse, Montpellier, and Bordeaux, IRDI Capital Investissement has been a key player in private equity for more than 35 years, with an investment track record in companies located in the South-West of France and at all development stages. It manages more than €350 million spread across several funds, including IRDINOV 2 and INN’VEST PME OCCITANIE EST which were both leveraged to invest in AcuSurgical.
IRDINOV 2 - supported by the Fonds National d’Amorçage (FNA) - is a capital seed fund specialized in financing technological companies.
INN’VEST PME OCCITANIE EST is a co-investment fund supported by the European Investment Fund (EIF) and the Région Occitanie under the FOSTER TPE PME fund of funds.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210217005035/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Eventbrite Enters into Definitive Agreement to Be Acquired by Bending Spoons for Roughly $500 Million to Accelerate Eventbrite’s Next Phase of Growth2.12.2025 13:30:00 CET | Press release
Eventbrite stockholders to receive $4.50 per share in cash Eventbrite, Inc. (NYSE: EB), the leading global marketplace for shared experiences, announced today that it has entered into a definitive agreement to be acquired by Bending Spoons, in an all-cash transaction valued at approximately $500 million. The acquisition is subject to customary closing conditions and approvals, including regulatory approvals and approval by Eventbrite’s stockholders. “For two decades, Eventbrite has stood at the forefront of the experience economy, helping tens of millions to create, discover, and attend unforgettable events,” said Luca Ferrari, Bending Spoons CEO and Co-Founder. “Joining forces with Bending Spoons will accelerate innovation and strengthen Eventbrite’s tools and resources to bring even more people together through shared live experiences for many years to come. As longstanding fans, we’ve identified a few opportunities that we’re excited about exploring with the Eventbrite team after cl
Armis Recognized for Innovation; Named to Inc. Best in Business List for the Second Consecutive Year2.12.2025 13:00:00 CET | Press release
Annual list spotlights companies and leaders delivering meaningful results for their industries, customers and future growth Armis, the cyber exposure management & security company, today announced that it has once again been named to Inc.’s Best in Business list, specifically highlighted in the Best in Innovation category for 2025. Inc.’s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made a profound impact on their industries and on society at large. “Armis rapidly innovates and continuously enhances our comprehensive Cyber Exposure Management Platform so that global organizations can proactively protect against cyber threats before there’s any impact,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “Unlike other solutions on the market, Armis addresses the entire lifecycle of managing cyber threats so that security teams no longer reactively respond to breaches. This is a strategic and monumental shift for the indust
Egle Therapeutics Initiates Phase 1 Healthy Volunteer Study of EGL-003, a Next Generation Treg IL-2 Agonist for Atopic Dermatitis2.12.2025 12:32:00 CET | Press release
Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company developing precision medicines that modulate regulatory T cells (Tregs) to restore immune balance, today announced dosing of the first healthy volunteer in the Phase 1 clinical study of EGL-003, an IL‑2⍺-biased mutein designed to selectively activate Tregs while limiting effector T cell stimulation, as a potential treatment for atopic dermatitis. The open-label, multi-center Phase 1 trial begins with a single ascending dose portion in healthy volunteers to rapidly generate foundational safety, pharmacokinetic (PK), and pharmacodynamic (PD) data. These findings will inform dose selection and scheduling for the subsequent multiple ascending dose portion in approximately 40 adults with atopic dermatitis (AD), which will evaluate safety, PK/PD, and early clinical activity versus placebo. Data from both study segments are expected to guide dose selection for a planned Phase 2a trial in AD aimed at establishing clinical pro
AI Takes Center Stage as the Major Threat to Cybersecurity in 20262.12.2025 12:00:00 CET | Press release
Experian releases its 13th Annual Data Breach Industry Forecast highlighting six predictions for 2026 that include several ways AI may have an impact Experian® today released its 2026 Data Breach Industry Forecast, offering a look at the evolving cyber threat landscape. The predictions address how the coming year could usher in a new wave of sophisticated attacks driven by artificial intelligence along with other threats and vulnerabilities including quantum computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202474758/en/ Experian's 2026 Data Breach Industry Forecast Now in its 13th year, the forecast offers six insights into how cybercriminals are leveraging emerging technologies to create more convincing identities, evade detection, and exploit new digital frontiers. From synthetic profiles and autonomous AI agents to shape-shifting malware and even brain-computer interface vulnerabilities, the 2026 predictions p
Buro Happold Signs Landmark Agreement with Expo 2030 Riyadh Company to Deliver Detailed Master Plan and Infrastructure and Public Realm Design for Expo 2030 Riyadh2.12.2025 11:00:00 CET | Press release
Buro Happold, a leading global engineering, design and advisory consultancy, has signed a major contract with Expo 2030 Riyadh Company to serve as the lead design consultant for the detailed master plan and detailed design of public realm, landscape, infrastructure and utilities for Expo 2030 Riyadh and its legacy. This partnership represents a significant step toward delivering an event billed as “An Unprecedented World Expo”. Expo 2030 Riyadh is expected to feature nearly 197 participating countries and attract over 42 million visits to Pavilions covering approximately 6 million sqm. The event will offer a unique opportunity for participants to address shared challenges and showcase pioneering solutions for a sustainable future. Under the agreement, Buro Happold will provide comprehensive design and technical services, including, development of the detailed master plan, including a focus on event requirements and legacy phase elements, detailed design of the infrastructure works, uti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom